Mudgal Pallavi, Kumar Gupta Sonu, Malik Sunny, Nith Rinkal B, Kumar Sunil, K Rahul, Chaturvedi Kartikey, Kumar Yashwant
Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India, 121001.
Department of Chemistry, School of Basic and Applied Sciences, Lingaya's Vidyapeeth, Faridabad, Haryana, India, 121002.
Metabolomics. 2025 Aug 12;21(5):116. doi: 10.1007/s11306-025-02312-5.
Despite its prevalence and the significance of early diagnosis, non-alcoholic fatty liver disease (NAFLD), one of the most prevalent liver diseases globally and frequently linked to elements of metabolic syndrome, lacks robustly validated biomarkers for diagnosis, prognosis, and tracking of disease progression in response to a particular treatment.
The aim of this study was to catalogue the metabolites from metabolomics data reported by different studies till date, and to find few majorly dysregulated metabolites that can potentially be used as progressive biomarkers of NAFLD in future.
The clinical data published during last 13 years was investigated and further curated from established databases of MEDLINE, EMBASE and PUBMED on NAFLD. A vote-counting method was used to perform a semi-quantitative meta-analysis of metabolites in serum/blood from NAFLD subjects.
This analysis unveiled the well-unprecedented changes in the metabolites of different classes as amino acids Valine, isoleucine, glutamate, tyrosine, alpha-ketoglutarate and phenylalanine were found to be up-regulated whereas glycine, serine and arginine were observed to be down-regulated. This investigation envisaged role of a few metabolites which were significantly distinct in the progression of NAFLD condition.
This study highlighted the role of different metabolites in the progression of NAFLD condition. However, the analysis also reveals certain limitations requiring better standardization of metabolomics investigations, signifying errors and lacunas of metabolic databases in identification and reporting. Additionally, inadequate publicly accessible metabolomics data, limits the discovery potential of meta-analyses of clinical studies.
非酒精性脂肪性肝病（NAFLD）是全球最常见的肝脏疾病之一，常与代谢综合征的要素相关联，尽管其患病率高且早期诊断意义重大，但在诊断、预后以及追踪疾病对特定治疗的进展方面，仍缺乏经过充分验证的生物标志物。
本研究的目的是梳理迄今为止不同研究报告的代谢组学数据中的代谢物，并找出一些可能在未来用作NAFLD进展生物标志物的主要失调代谢物。
调查并进一步整理了过去13年期间从MEDLINE、EMBASE和PUBMED等已建立的NAFLD数据库中发表的临床数据。采用投票计数法对NAFLD受试者血清/血液中的代谢物进行半定量荟萃分析。
该分析揭示了不同类别的代谢物出现了前所未有的变化，发现氨基酸缬氨酸、异亮氨酸、谷氨酸、酪氨酸、α-酮戊二酸和苯丙氨酸上调，而甘氨酸、丝氨酸和精氨酸下调。本研究设想了一些代谢物在NAFLD病情进展中的显著不同作用。
本研究强调了不同代谢物在NAFLD病情进展中的作用。然而，分析也揭示了某些局限性，需要更好地规范代谢组学研究，表明代谢数据库在识别和报告方面存在错误和缺陷。此外，公开可用的代谢组学数据不足，限制了临床研究荟萃分析的发现潜力。
